Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks based on value, growth, and momentum characteristics, assigning ratings from A to F [4] - Value Score focuses on identifying undervalued stocks using financial ratios [4] - Growth Score evaluates a company's financial health and future growth potential [5] - Momentum Score identifies optimal times to invest based on price trends and earnings estimates [6] - VGM Score combines all three styles, providing a comprehensive rating for stocks [7] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988 [8] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for optimal returns [10] Company Spotlight: Array Technologies, Inc. - Array Technologies, Inc. is a biopharmaceutical company focused on targeted small molecule drugs for cancer treatment [12] - The company has a marketed therapy, Braftovi plus Mektovi, approved for specific melanoma cases [12] - Array Technologies holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong investment potential [13] - The company has a forward P/E ratio of 10.83, appealing to value investors [13] - Recent upward revisions in earnings estimates suggest positive momentum, with a consensus estimate of $0.66 per share for fiscal 2025 [13] - With solid rankings and scores, Array Technologies is recommended for investors [14]

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phas ...

Deep application provides foundation for commercial executionPLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities."We are excited to expand our strategic partnership with Veeva ...

EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company’s June 27, 2025 announcement of the agreements to c ...

Core Viewpoint - ZyVersa Therapeutics is positioned to advance its pipeline of first-in-class drugs for renal and inflammatory diseases despite challenging market conditions, emphasizing the importance of continued investor support [2][3][4]. Financial Developments - In Q2-2025, ZyVersa secured $12 million in capital through two financing transactions: a $2 million warrant inducement transaction and a Share Purchase Agreement for up to $10 million with Williamsburg Venture Holdings [5]. Product Pipeline - VAR 200 targets kidney diseases by addressing lipid accumulation in the kidneys, with ongoing trials for focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease (DKD) [6][8]. - Preliminary data for the Phase 2a trial in DKD is expected in Q4-2025, with final results anticipated in H1-2026 [6]. - IC 100 is an inflammasome inhibitor aimed at treating obesity and potentially neurological diseases, with preclinical studies planned for Q3-2025 [11]. Market Opportunity - Kidney disease affects over 850 million people globally, with significant unmet medical needs and limited treatment options, representing a substantial market opportunity [8][9]. - The U.S. spends over $130 billion annually on kidney disease, accounting for approximately 25% of Medicare spending [9]. Regulatory Environment - Regulatory bodies like the FDA and EMA are facilitating innovation in kidney disease treatment through accelerated pathways, which may reduce barriers to drug development [14].

Core Viewpoint - Amneal Pharmaceuticals, Inc. is seeking to raise $1.800 billion through new seven-year term B loans and $750 million through senior secured notes to refinance existing debts and manage related expenses [1][2]. Group 1: Financing Details - The net proceeds from the new term B loans and the notes will be used to refinance existing term B loans in full, repay part of the amounts borrowed under the ABL facility, and cover related fees and expenses [2]. - The notes will be guaranteed on a senior secured basis by the same subsidiaries that will guarantee the Term Loan Facility, and will not be guaranteed by Amneal itself [3]. - The notes will have a first-priority lien on collateral, excluding ABL priority collateral, and a second-priority lien on ABL priority collateral [3]. Group 2: Regulatory and Market Considerations - The proposed transactions are subject to market conditions and other factors, with no assurance on the completion or terms of the transactions [4]. - The notes will not be registered under the Securities Act of 1933 and will only be offered to qualified institutional buyers and non-U.S. persons [5]. Group 3: Company Overview - Amneal is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a diverse portfolio of over 280 pharmaceuticals, primarily in the U.S. [7]. - The company is expanding its Affordable Medicines segment across various complex product categories and therapeutic areas, including injectables and biosimilars [7].

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative tre ...

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company expects procee ...

PITTSBURGH, July 21, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. The manuscript, titled Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Cli ...

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host its Frontiers in B ...